Literature DB >> 28221819

A Prospective Study of Endoscopic Injection Sclerotherapy and Endoscopic Variceal Ligation in the Treatment of Esophageal Varices.

Syed Mohsin Ali1, Shanbin Wu2, Hongwei Xu1, Hui Liu1, Jinghua Hao1, Chengyong Qin1.   

Abstract

INTRODUCTION: The aim of this study was to compare the effectiveness and safety of endoscopic injection sclerotherapy (EIS) with endoscopic variceal ligation (EVL) in the management of esophageal variceal bleeding (EVB). PATIENTS AND METHODS: In this prospective study, we compared the EIS and EVL in 124 patients who had endoscopically proved bleeding from esophageal varices. According to different treatment methods, they were randomly divided into the EIS and the EVL groups. Sixty-four patients were treated with sclerotherapy and 60 with ligation. The patients were followed for a mean of 2 years, during which we determined the incidence of complications and recurrences of bleeding and the number of treatment sessions needed to eradicate varices, mortality, and survival.
RESULTS: Active bleeding at the first treatment was controlled by EIS in 19 of 19 patients and by EVL in 16 of 16 patients. The likelihood of early rebleeding was slightly smaller in the patients treated with EIS (7.8% versus 11.7%, P = .47). However, late rebleeding rate was slightly more in EIS patients (28.1% versus 23.3%, P = .54) without statistical significance. The rate of eradication of varices in the EIS group was slightly lower than in the EVL group (79.7% versus 86.7%, P = .30). There were also no statistically significant differences in mortality (1.6% versus 3.3%, P = .61) or survival rate (71.9% versus 78.3%, P = .41) (all P > .05) after EIS and EVL. However, fever in the EIS group was significantly higher compared to that of in the EVL group (n = 17, 26.6% versus n = 6, 10.0%, P = .02).
CONCLUSIONS: Both EIS and EVL produce excellent results, are safe, effective, feasible, and acceptable for EVB with minimum complications and obviate need for subsequent procedures in the short term. To make better choice, we should consider the hospital conditions, operator experience, and the characteristics of esophageal varices.

Entities:  

Keywords:  endoscopic injection sclerotherapy; endoscopic variceal ligation; esophageal variceal bleeding

Mesh:

Substances:

Year:  2016        PMID: 28221819     DOI: 10.1089/lap.2016.0436

Source DB:  PubMed          Journal:  J Laparoendosc Adv Surg Tech A        ISSN: 1092-6429            Impact factor:   1.878


  5 in total

1.  A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification.

Authors:  Tsuyoshi Ishikawa; Ryo Sasaki; Tatsuro Nishimura; Yuki Aibe; Issei Saeki; Takuya Iwamoto; Isao Hidaka; Taro Takami; Isao Sakaida
Journal:  PLoS One       Date:  2019-09-26       Impact factor: 3.240

2.  Defining the advantages and exposing the limitations of endoscopic variceal ligation in controlling acute bleeding and achieving complete variceal eradication.

Authors:  Jake Krige; Eduard Jonas; Urda Kotze; Christo Kloppers; Karan Gandhi; Hisham Allam; Marc Bernon; Sean Burmeister; Mashiko Setshedi
Journal:  World J Gastrointest Endosc       Date:  2020-10-16

3.  Different Doses of Oxycodone for Endoscopic Injection Sclerotherapy of Esophageal Varices.

Authors:  Jie Yao; ChunXiao Song; Chen Zhou; HaiLi He; ZheFeng Quan
Journal:  Med Sci Monit       Date:  2021-03-17

4.  Esophageal Variceal Ligation Monotherapy versus Combined Ligation and Sclerotherapy for the Treatment of Esophageal Varices.

Authors:  Jianbo Wang; Shenghui Chen; Yehia M Naga; Junwei Liu; Mugen Dai; Shangwen Yang; Liangjing Wang; Bin Ye
Journal:  Can J Gastroenterol Hepatol       Date:  2021-03-29

5.  Novel balloon compression-assisted endoscopic injection sclerotherapy and endoscopic variceal ligation in the treatment of esophageal varices: a prospective randomized study.

Authors:  Qianqian Zhang; Jing Jin; Fumin Zhang; Yi Xiang; Wenyue Wu; ZeXue Wang; Derun Kong
Journal:  Surg Endosc       Date:  2022-07-25       Impact factor: 3.453

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.